Verona Pharma Plc is a London-based biopharmaceutical company focused on creating treatments for respiratory diseases lacking adequate therapies. Its leading product, ensifentrine, is a novel compound with dual action as a bronchodilator and anti-inflammatory agent, currently in Phase 3 trials for conditions like chronic obstructive pulmonary disease, asthma, and cystic fibrosis. Verona Pharma is exploring ensifentrine in various forms, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler, aiming to meet critical healthcare needs.
Live Updates An American TikTok?11:46am ETReuters reports that TikTok will launch a standalone app for U.S. users, powered by a different algorithm from the Chinese original. Such a move could pave a…
Tuesday's top analyst upgrades and downgrades included Apple, Azul, Conagra Brands, Corteva, CSX, Deere, DraftKings, Foot Locker, Intuit, KeyCorp, Nike, Salesforce, Take-Two Interactive Software, Union Pacific and Zions Bancorp.
Tuesday's top analyst upgrades and downgrades included Adobe, Cheniere Energy, CNX Resources, Edwards Lifesciences, EOG Resources, Huntsman, Kraft Heinz, NCR, Peloton Interactive, PulteGroup, Take-Two Interactive Software and UDR.
Monday's additional top analyst upgrades and downgrades were on Array Technologies, ConocoPhillips, EQT, KB Home, Lennar, NetApp, Netflix and more.
Monday’s top analyst upgrades and downgrades included Affirm, AstraZeneca, Broadcom, Centene, Dell Technologies, Dollar General, Marvell Technology, Medical Properties Trust, Tesla, Ulta Beauty, Union Pacific and Workday.
Friday's additional top analyst upgrades and downgrades were on Burlington Stores, Forge Global, Gap, Ulta Beauty, Zoom Video Communications and more.
Monday's top analyst upgrades and downgrades included Albermarle, Apple, Consolidated Edison, Etsy, GoHealth, Hecla Mining, NortonLifeLock, Pinterest, Switch and T-Mobile.
